How Cannabis Helps MS Symptoms
MS causes immune-mediated demyelination of neurons, leading to spasticity, pain, bladder dysfunction, and fatigue. CB1 receptors in the spinal cord and CB2 receptors in immune cells are both relevant targets. THC reduces spasticity by inhibiting motor neuron excitability. CBD has neuroprotective and anti-inflammatory properties that may slow inflammatory progression. The approved pharmaceutical Sativex uses a 1:1 THC:CBD ratio — mirrored by many medical cannabis preparations. Anti-inflammatory cannabinoid effects are central to MS management. THC and CBD together are more effective than either alone for MS spasticity.
Clinical Evidence & Research
The CAMS trial (Cannabis in Multiple Sclerosis) — a landmark UK randomised controlled trial — demonstrated significant improvements in spasticity, pain, and sleep with cannabis extract. Sativex's approval in 29 countries is based on multiple Phase III trials showing clinically significant spasticity reduction versus placebo. A 2017 systematic review found high-quality evidence that cannabis is effective for MS spasticity. Germany approved Sativex specifically for MS spasticity, and the Netherlands provides cannabis through pharmacies for MS patients.
Access & Patient Requirements
MS is a qualifying condition in 35+ US medical cannabis states and in most European countries with medical cannabis programmes. A confirmed MS diagnosis (typically by MRI and neurological evaluation) is required. Many states require documented spasticity scoring and failed conventional antispasticity treatments (baclofen, tizanidine). California, Colorado, and New York all include MS explicitly in their qualifying condition lists.
Recommended Cannabis Approaches for MS
A 1:1 THC:CBD ratio mirrors Sativex's approved formulation and is the most evidence-supported starting point. Oromucosal administration (sublingual spray or tincture) provides faster onset and better dose control than oral capsules. Vaporisation is preferred by patients needing rapid relief from acute spasticity episodes. Topical preparations address localised muscle spasm without systemic effects. Harlequin (CBD-rich) and balanced hybrids are well-suited for daytime MS symptom management. The beta-caryophyllene terpene adds meaningful anti-inflammatory benefit.